Stakeholders in the US Tissue Banking Market are exploring different business models to maintain operations and scale. Non‐profit or academic tissue banks often rely on grants, philanthropic donations, and government funding; commercial banks may depend more heavily on service fees, licensing, and partnerships with biotech companies. Hybrid models, combining public support and commercial activity, may offer resilience: leveraging donor programs, efficient processing, and downstream commercialization of engineered tissues or therapeutic products. Sustainable funding must cover expensive infrastructure (cryogenic storage, cleanrooms), skilled staff, regulatory compliance, insurance liability, and patient safety. Because tissue preservation often involves long‐term storage with uncertain future demand, balancing inventory costs with utilization rates is tricky. Transparent pricing, cost recovery models, and stakeholder engagement are necessary for credibility and financial stability.

In discussion, evaluate which funding models offer the best balance of quality, accessibility, and sustainability. Should more tissue banks adopt hybrid models, or will commercial pressures compromise ethics? Also consider government policies or reimbursement schemes that can support tissue banking. Discuss risks of over-investment leading to surplus capacity vs under-investment leading to shortages. Finally, what metrics or KPIs should tissue banks track to ensure long-term financial health?